Sharemaestro Newsreel

BioAge Labs, Inc. reports results for the quarter ended June 30 - Earnings Summary

BioAge Labs, Inc. has released its earnings summary for the quarter that concluded on June 30. The article, sourced from Reuters and published on TradingView, provides an overview of the company's financial performance. Readers are encouraged to access the full article on TradingView for …

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda announced that the U.S. FDA has approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for treating narcolepsy type 1 (NT1) in adults. This first-in-class medicine targets the underlying orexin deficiency, offering holistic treatment beyond symptom relief. The availability of ORZEYFUL is …

Organigram (TSX:OGI) Strengthens Global Reach Through Germany Expansion

Organigram (TSX:OGI) is expanding its global presence by strengthening its operations in Germany, a rapidly growing regulated medical cannabis market. This European expansion aims to diversify the company's business beyond Canada's domestic industry and leverage local healthcare, distribution, and patient access capabilities provided by …

Biofrontera schedules Aug. 13 webcast for business update

Biofrontera Inc. (NASDAQ: BFRI) announced it will report its second-quarter 2026 financial results on Thursday, August 13, 2026, before market open. Management will host a conference call and webcast at 10:00 a.m. Eastern Time on the same day to discuss the results and provide …

Evolus Q2 2026 slides: profitability streak continues, guidance raised

Evolus Inc. reported strong Q2 2026 results, with revenue up 21% year-over-year to $84.1 million, marking its third consecutive quarter of positive adjusted EBITDA. The company raised its full-year 2026 revenue guidance to $330-$337 million and reaffirmed its long-term target of $450-$500 million by …

Emergent BioSolutions Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:EBS) 2026-08-05

Key Points Interested in Emergent Biosolutions Inc.? Here are five stocks we like better. Q2 performance exceeded expectations: Revenue reached $234 million and adjusted EBITDA rose to $97 million, driven by accelerated medical countermeasure deliveries and strong U.S. government contract activity. NARCAN competition is …

Talphera will webcast its second-quarter financial update Aug. 12

Talphera (Nasdaq: TLPH) announced it will host a conference call and webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET to discuss its second-quarter 2026 financial results and recent business progress. Investors can access the call via dial-in numbers provided or a live …

Talphera schedules Q2 2026 results conference call and webcast

Talphera has scheduled a conference call and webcast for August 12, 2026, to discuss its second-quarter 2026 financial results and recent business developments. A replay of the webcast will be available for 90 days on the company's website. This news brief was generated by …

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

Talphera, Inc. announced it will report its second-quarter 2026 financial results on Wednesday, August 12, 2026. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and recent business progress. Talphera is a specialty pharmaceutical company developing …

Haleon plc Stock 12‑Month Price Target Raised to $11.29, Implies 15% Upside

Haleon plc's average 12-month price target has been increased from $11.23 to $11.29 by 15 analysts, with individual forecasts ranging from $8.46 to $13.82. This updated target suggests a potential upside of approximately 15% from the Aug. 4 closing price. The consensus rating from …

Teknova Reports Second Quarter 2026 Financial Results

Teknova (Nasdaq: TKNO) announced strong financial results for the second quarter of 2026, with total revenue reaching $12.2 million, an 18% increase year-over-year. The company also raised its full-year 2026 revenue guidance to $45-$47 million and introduced its AI-powered Build-Tek™ custom order configurator to …

Teknova Q2 2026 Earnings: Revenue Growth Drives Higher Guidance

Teknova (Nasdaq: TKNO) reported a strong Q2 2026 with revenue up 18% to $12.2 million, narrowing its GAAP diluted EPS loss to $0.06. The company saw broad-based growth across its Lab Essentials and Clinical Solutions segments, leading to improved operating leverage and significantly reduced …

Teva Pharmaceutical (TEVA) R&D chief exercises RSUs, sells shares

Teva Pharmaceutical Industries' Executive Vice President, Global R&D and Chief Medical Officer, Eric A. Hughes, exercised 52,744 restricted share units (RSUs) on August 3, 2026. Subsequently, he sold 25,578 ordinary shares at a weighted average price of $34.8757 per share to cover tax withholding …

Teva Pharmaceutical Industries (TEVA) exec sells 12,827 shares under 10b5-1 plan

Teva Pharmaceutical Industries executive Placid Jover sold 12,827 ordinary shares for approximately $447,000 on August 3, 2026, after converting restricted share units. The sale was executed under a Rule 10b5-1 trading plan to cover tax withholding obligations. Following the transaction, Jover retains 25,657 restricted …

Tilray Brands Inc. stock falls Wednesday, underperforms market

Tilray Brands Inc. (TLRY) shares fell 4.63% to $4.43 on Wednesday, underperforming a mixed market session where the Dow Jones Industrial Average rose and the NASDAQ Composite Index declined. The stock closed significantly below its 52-week high of $23.20.

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

BioAge Labs reported its second-quarter 2026 financial results, highlighting progress in its clinical development programs for BGE-102, an oral NLRP3 inhibitor. The company announced the first participant dosed in its QUELL-CV Phase 2 trial for obesity and inflammation, with topline data expected in late …

BioAge Labs (NASDAQ: BIOA) builds $381.3M cash buffer as BGE-102 advances

BioAge Labs reported a net loss of $48.4 million for the first half of 2026 but holds a strong cash position of $381.3 million, expected to fund operations through 2029. The company is advancing its lead candidate BGE-102, an NLRP3 inhibitor, with positive Phase …

BioAge's BGE-102 Enters Obesity Trial; Eye Study Planned

BioAge Labs reported a Q2 2026 net loss of $26.1 million on collaboration revenue of $2.4 million, with increased R&D expenses driven by its BGE-102 program. The company has dosed the first participant in its Phase 2 QUELL-CV trial for obesity with inflammation, expecting …

Aurora Cannabis Inc. stock rises Wednesday, outperforms market

Aurora Cannabis Inc. (ACB) saw its stock rise by 3.56% on Wednesday, closing at $2.91. This performance outpaced the broader market, as the Dow Jones Industrial Average gained 0.49% while the NASDAQ Composite Index fell 0.83%. Despite the daily gain, the company's stock remains …

Neurocrine Biosciences (NBIX) CSO Jude Onyia makes bona fide stock gift

Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences (NBIX), made a bona fide gift of 2,409 shares of common stock effective August 4, 2026. This transaction was a charitable contribution, not a market sale, and no value was received for the shares. After this …

Evolus (EOLS) Releases Q2 2026 Earnings: Revenue Growth and Narrower Losses

Evolus (EOLS) reported strong Q2 2026 earnings, with revenue reaching $84.1 million, a 21.2% increase year-over-year, and slightly exceeding analyst estimates. The company also improved its financial performance by narrowing its operating and net losses. Insider trading activity showed sales by executives, while institutional …

Evolus (Nasdaq: EOLS) posts higher sales and manages sizable debt load

Emergent BioSolutions Reports Second Quarter 2026 Financial Results

Emergent BioSolutions announced its second-quarter 2026 financial results, reporting total revenues of $234.3 million, a 66% increase year-over-year, and an adjusted net income of $30.9 million, up 134%. Despite a significant net loss due to a non-cash impairment charge, the company is implementing a …

BofA cuts United Therapeutics stock price target on Tyvaso sales

BofA Securities lowered its price target for United Therapeutics Corp. (NASDAQ:UTHR) to $559 from $613, while maintaining a Neutral rating, due to weaker-than-expected Tyvaso sales and competitive pressures. The company's second-quarter results included a revenue miss, leading BofA to reduce its fiscal 2026 sales …

Baslake group (TXMD) discloses 6.8% beneficial stake in TherapeuticsMD common stock

Baslake Partners, LP, along with Baselake Management, LLC and David Paolella, has reported a beneficial ownership of 6.8% in TherapeuticsMD, Inc. common stock. This stake represents 790,703 shares, with shared voting and dispositive power among the reporting persons. The ownership percentage is based on …

Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments

The FDA has approved Takeda's narcolepsy drug, Orzeyful, a twice-daily pill that is an orexin receptor agonist. This approval is significant as it marks a new class of treatment for narcolepsy type 1, offering an alternative to existing therapies which have risks of misuse …

Evolus (NASDAQ: EOLS) lifts 2026 guidance after Q2 revenue hits $84.1 million

Evolus (NASDAQ: EOLS) reported strong Q2 2026 financial results with net revenue of $84.1 million, a 21% increase year-over-year, and positive adjusted EBITDA of $4.7 million. This marks the third consecutive quarter of positive adjusted EBITDA for the company. Consequently, Evolus has raised its …

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Akebia Therapeutics announced strong second-quarter 2026 financial results, with Vafseo net product revenues growing to $21.3 million and over 10,500 patients on therapy. The company also highlighted significant advancements in its rare kidney disease pipeline, including the initiation of a Phase 2 trial for …

Emergent records $191.3M non-cash charge related to NARCAN asset group

Emergent BioSolutions reported Q2 2026 total revenues of $234.3 million, a 66% increase year-over-year, driven primarily by higher U.S. government sales of smallpox and other medical countermeasure products. Despite this revenue growth and improved adjusted net income and EBITDA, the company posted a GAAP …

Kamada Ltd. (KMDA) investors back all proposals at 2026 annual meeting

Kamada Ltd. announced that its shareholders approved all proposals at the Annual General Meeting held on August 5, 2026, at the company's headquarters in Rehovot, Israel. These proposals included the re-election of directors, approval of option grants, an amendment to the U.S. Taxpayers Appendix …

Earnings Flash (PRGO) Perrigo Company Plc Posts Q2 Adjusted EPS $0.50 per Share, Vs. FactSet Est of $0.34

Perrigo Company Plc (PRGO) announced its second-quarter adjusted EPS of $0.50 per share, significantly exceeding the FactSet estimate of $0.34 per share. This financial beat indicates a stronger performance than anticipated by analysts for the quarter.

Pacira BioSciences (NASDAQ: PCRX) earns Q2 profit and sells iovera business

Pacira BioSciences (NASDAQ: PCRX) reported a profit in Q2 2026 with total revenues of $192.4 million, driven by strong sales of EXPAREL and ZILRETTA. The company also announced the divestiture of its iovera° cryoanalgesia business to Zimmer for up to $140 million, including an …

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

Biofrontera Inc. (NASDAQ: BFRI), a U.S. specialty dermatology company, announced it will report its second-quarter 2026 financial results on Thursday, August 13, 2026, before the market opens. Following the release, management will host a conference call and webcast at 10:00 a.m. Eastern Time to …

Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment

Emergent BioSolutions (NYSE: EBS) emphasizes the critical need for cross-sector collaboration to address evolving biological threats stemming from geopolitical conflicts, AI, and synthetic biology. The company highlights calls from European health officials and AI industry leaders for stronger safeguards and points to recent anthrax-related …

Perrigo Company plc 2026 Q2 - Results - Earnings Call Presentation (NYSE:PRGO)

Perrigo Company plc (NYSE:PRGO) released its Q2 2026 earnings call presentation on August 5, 2026. The company reported an EPS of $0.50, beating estimates by $0.15, and revenue of $1.02 billion, exceeding expectations by $12.65 million despite a 3.17% year-over-year decrease. This presentation provides …

Pacira BioSciences Q2 Earnings Call Highlights

Pacira BioSciences reported a 6% increase in Q2 2026 revenue to $192.4 million, driven by strong sales of EXPAREL, ZILRETTA, and iovera°. The company highlighted expanded payer coverage for EXPAREL and progress in its pipeline, while also completing the sale of iovera° to Zimmer …